A Phase 1, Open-Label, Randomized, Single Dose, 3-Way Crossover Study to Assess the Relative Bioavailability of Solifenacin Liquid Suspension 10 mg (Formulation B) Versus Solifenacin Liquid Suspension 10 mg (Formulation A) and to Assess the Relative Bioavailability of Solifenacin Liquid Suspension 10 mg (Formulation A and B) Versus the VESIcare (Solifenacin Succinate) 10 mg Tablet in Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 23 Aug 2011
At a glance
- Drugs Solifenacin (Primary)
- Indications Overactive bladder
- Focus Pharmacokinetics
- 23 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Aug 2011 New trial record